UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $1.24 Billion Stake in Thermo Fisher Scientific Inc. $TMO

Posted by Stanley Muller on Aug 30th, 2026

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO – Free Report) by 0.9% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 2,472,524 shares of the medical research company’s stock after buying an additional 22,827 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned approximately 0.67% of Thermo Fisher Scientific worth $1,239,625,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also modified their holdings of the company. Legacy Wealth Managment LLC ID increased its stake in Thermo Fisher Scientific by 78.6% in the first quarter. Legacy Wealth Managment LLC ID now owns 50 shares of the medical research company’s stock valued at $25,000 after purchasing an additional 22 shares in the last quarter. Kilter Group LLC acquired a new position in shares of Thermo Fisher Scientific in the 2nd quarter valued at $25,000. Allied Private Wealth LLC bought a new stake in shares of Thermo Fisher Scientific in the 2nd quarter valued at $26,000. High Note Wealth LLC raised its stake in Thermo Fisher Scientific by 170.6% during the 4th quarter. High Note Wealth LLC now owns 46 shares of the medical research company’s stock worth $27,000 after buying an additional 29 shares during the period. Finally, Swiss RE Ltd. bought a new position in Thermo Fisher Scientific during the fourth quarter worth about $28,000. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, CAO Joseph R. Holmes sold 420 shares of the firm’s stock in a transaction on Friday, August 7th. The stock was sold at an average price of $584.81, for a total value of $245,620.20. Following the transaction, the chief accounting officer owned 2,966 shares in the company, valued at approximately $1,734,546.46. This trade represents a 12.40% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, VP Lisa P. Britt sold 11,440 shares of the business’s stock in a transaction dated Wednesday, August 19th. The shares were sold at an average price of $613.12, for a total value of $7,014,092.80. Following the completion of the transaction, the vice president directly owned 14,784 shares of the company’s stock, valued at approximately $9,064,366.08. This trade represents a 43.62% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 73,768 shares of company stock valued at $44,122,820. 0.33% of the stock is currently owned by corporate insiders.

Thermo Fisher Scientific Price Performance

Thermo Fisher Scientific stock opened at $621.87 on Friday. The company has a current ratio of 1.55, a quick ratio of 1.18 and a debt-to-equity ratio of 0.74. The stock’s 50 day moving average is $558.64 and its 200-day moving average is $512.08. Thermo Fisher Scientific Inc. has a 12 month low of $435.27 and a 12 month high of $647.00. The company has a market capitalization of $229.94 billion, a price-to-earnings ratio of 33.45, a PEG ratio of 2.53 and a beta of 0.85.

Thermo Fisher Scientific (NYSE:TMO – Get Free Report) last posted its quarterly earnings data on Thursday, July 23rd. The medical research company reported $6.03 earnings per share for the quarter, topping the consensus estimate of $5.71 by $0.32. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.The firm had revenue of $11.99 billion for the quarter, compared to analysts’ expectations of $11.71 billion. During the same quarter last year, the business earned $4.28 EPS. The company’s quarterly revenue was up 10.5% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. Equities research analysts expect that Thermo Fisher Scientific Inc. will post 25.13 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, October 15th. Stockholders of record on Tuesday, September 15th will be issued a dividend of $0.47 per share. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $1.88 annualized dividend and a dividend yield of 0.3%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 10.11%.

Wall Street Analyst Weigh In

A number of research firms have issued reports on TMO. Wall Street Zen raised Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research note on Saturday, August 1st. Piper Sandler lifted their price objective on Thermo Fisher Scientific from $510.00 to $600.00 and gave the company a “neutral” rating in a report on Monday, July 27th. Royal Bank Of Canada increased their target price on Thermo Fisher Scientific from $490.00 to $580.00 and gave the stock a “sector perform” rating in a research note on Friday, July 24th. KeyCorp restated an “overweight” rating on shares of Thermo Fisher Scientific in a report on Tuesday, May 26th. Finally, Stifel Nicolaus set a $650.00 price target on shares of Thermo Fisher Scientific in a report on Wednesday, August 5th. One analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat, Thermo Fisher Scientific currently has a consensus rating of “Moderate Buy” and a consensus target price of $619.41.

Check Out Our Latest Report on TMO

About Thermo Fisher Scientific

(Free Report)

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.